ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,977Medicare Part D Prescriptions Filled, Including Refills

Rank: 22 out of 623

$680K Total Retail Price of All Prescriptions

Rank: 16 out of 623

224 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
90% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

13% of this provider’s 224 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 9,158 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

45 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 410 381 1 4
LISINOPRIL 346 343 2 1
AMLODIPINE BESYLATE 336 321 3 3
SIMVASTATIN 317 279 4 2
MIRTAZAPINE 293 293 5 31
FUROSEMIDE 260 226 6 5
GABAPENTIN 235 225 7 18
METOPROLOL TARTRATE 230 217 8 9
CITALOPRAM HBR 210 188 9 21
NAMENDA 187 187 10 47
DONEPEZIL HCL 176 176 11 27
WARFARIN SODIUM 170 117 12 14
OMEPRAZOLE 169 144 13 7
TRAMADOL HCL 157 143 14 15
LACTULOSE 154 149 15 67
RANITIDINE HCL 141 141 16 23
KLOR-CON 10 137 125 17 119
TAMSULOSIN HCL 134 124 18 35
LIDODERM 133 119 19 82
POTASSIUM CHLORIDE 130 129 20 24
HYDRALAZINE HCL 112 112 21 70
SERTRALINE HCL 107 76 22 20
CARVEDILOL 103 100 23 32
LATANOPROST 102 94 24 140
TRAZODONE HCL 100 84 25 36
ALENDRONATE SODIUM 85 64 26 37
CYMBALTA 83 75 27 52
LOSARTAN POTASSIUM 83 70 27 16
LANTUS 71 69 29 41
METOCLOPRAMIDE HCL 71 71 29 165
LEVETIRACETAM 69 66 31 83
LEVOFLOXACIN 68 64 32 72
CLOPIDOGREL 68 62 32 34
CALCITONIN-SALMON 66 66 34 247
PLAVIX 66 60 34 46
DIGOXIN 66 66 34 63
RENVELA 65 53 37 205
ADVAIR DISKUS 65 57 37 39
QUETIAPINE FUMARATE 64 63 39 51
METFORMIN HCL 63 63 40 6
BUSPIRONE HCL 62 49 41 94
AMOX TR-POTASSIUM CLAVULANATE 56 45 42 132
PREDNISONE 55 43 43 40
NOVOLIN R 55 47 43 204
OLANZAPINE 55 55 43 120
BENZTROPINE MESYLATE 52 38 R 46 170
NOVOLOG 52 50 46 75
CLONIDINE HCL 52 52 46 55
CARBIDOPA-LEVODOPA 52 52 46 88
AMITIZA 52 52 46 281
COMBIVENT 51 51 51 154
ARANESP 50 50 52 209
IPRATROPIUM BROMIDE 50 50 52 133
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 29, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.